IN8bio, Inc.
INAB · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.02 | -0.00 | 0.86 | 0.52 |
| FCF Yield | -35.79% | -45.61% | -0.75% | -0.73% |
| EV / EBITDA | -0.55 | 0.29 | -73.54 | -101.41 |
| Quality | ||||
| ROIC | -23.87% | -27.75% | -30.58% | -31.90% |
| Gross Margin | 0.00% | 0.00% | 0.00% | -27.79% |
| Cash Conversion Ratio | 0.91 | 0.77 | 0.56 | 0.65 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 10.26% | -25.78% | 23.12% | 32.63% |
| Safety | ||||
| Net Debt / EBITDA | 2.01 | 1.98 | 1.37 | 1.12 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -68.49 | -120.63 | -27.72 |